Insulin-like growth factor I is expressed in classical and nodular lymphocyte-predominant Hodgkin's lymphoma tumour and microenvironmental cells by Eppler, Elisabeth et al.








Insulin-like growth factor I is expressed in classical and nodular
lymphocyte-predominant Hodgkin’s lymphoma tumour and
microenvironmental cells
Eppler, Elisabeth ; Janas, Eva ; Link, Karl ; Weidmann, Lukas ; Bischofberger, Helena ; Wenger,
Michael ; Tinguely, Marianne ; Schraml, Peter ; Moch, Holger ; Fellbaum, Christian
Abstract: Hodgkin’s lymphoma (HL) is among the most frequent nodal lymphomas in the Western
world and is classified into two disease entities: nodular lymphocyte-predominant Hodgkin’s lymphoma
(NLPHL) and classical Hodgkin’s lymphoma (cHL, 95 % of all HL). HL lesions are characterised by a
minority of clonal neoplastic cells, namely Hodgkin and Reed-Sternberg (HRS) cells and their variants
in cHL and lymphocyte-predominant (LP) cells in NLPHL, both occurring within a microenvironment
of, for example, reactive T and B cells, macrophages and granulocytes that are assumed to support
the proliferation and maintenance of neoplastic cells through cytokines, chemokines and growth factors.
Insulin-like growth factor I (IGF-I) is an important growth factor involved in proliferation, differentiation,
apoptosis and cell survival of numerous (including immune) tissues and probably has a role in tumour
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Abstract Hodgkin’s lymphoma (HL) is among the most fre-
quent nodal lymphomas in the Western world and is classified
into two disease entities: nodular lymphocyte-predominant
Hodgkin’s lymphoma (NLPHL) and classical Hodgkin’s lym-
phoma (cHL, 95% of all HL). HL lesions are characterised by
a minority of clonal neoplastic cells, namely Hodgkin and
Reed-Sternberg (HRS) cells and their variants in cHL and
lymphocyte-predominant (LP) cells in NLPHL, both occur-
ring within a microenvironment of, for example, reactive T
and B cells, macrophages and granulocytes that are assumed
to support the proliferation and maintenance of neoplastic
cells through cytokines, chemokines and growth factors.
Insulin-like growth factor I (IGF-I) is an important growth
factor involved in proliferation, differentiation, apoptosis and
cell survival of numerous (including immune) tissues and
probably has a role in tumour pathogenesis and maintenance.
Although HL is characterised by disturbed cell differentiation
and apoptosis mechanisms, with the involvement of the
IGF-I receptor (IGF-1R), the distinct location of IGF-I in HL
has not yet been defined. We localise IGF-I by double-
immunofluorescence in frequent neoplastic cells of all cHL
and NLPHL cases investigated. Additionally, IGF-I immuno-
reactivity is detected in high endothelial venules and various
immune cells within the surrounding tissue of cHL including
neutrophils and macrophages. IGF-1R immunoreactivity of
variable intensity is found in HRS cells and high endothelial
venules within the microenvironment in cHL. We assume that
autocrine and paracrine IGF-I plays an anti-apoptotic role in
tumour pathogenesis and in shaping the tumour
microenvironment.
Keywords IGF-I . IGF-1R . Growth factors . Hodgkin’s
disease . Reed-Sternberg cells . LP cells . Immune cells
Introduction
Hodgkin’s lymphoma (HL) is one of the most frequent nodal
lymphomas in the Western world (Roman and Smith 2011).
Current treatment protocols involving multi-agent chemother-
apy and/or radiotherapy achieve cure rates of 80–90 % (for a
review, see Küppers 2009) but approximately 40% of patients
are refractory to initial treatment or relapse after complete
remission.
HL represents a special group of malignancies, because
only about 0.5–2 % of the tumour mass is composed of
tumour cells, whereas the majority of cells within HL lesions
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are an infiltrate of various cell types of the immune system.
Classical HL (cHL) lesions are characterised by Hodgkin and
Reed-Sternberg (HRS) cells residing in a mixture of reactive
cells (Tand B cells, macrophages, plasma cells, granulocytes),
which are thought to support the proliferation of HRS cells
and the reactive cells within the tumour background through
cytokines and chemokines (Schmitz et al. 2009; Renné et al.
2009; Farrell and Jarrett 2011; Küppers et al. 2011). Important
progress has recently been made revealing the pathogenesis of
cHL; the tumour cells are assumed to be derived from germi-
nal centre B cells that have acquired disadvantageous muta-
tions in the immunoglobulin Ig variable chain gene (“crippled
mutation”), which should have undergone apoptosis but that
circumvent apoptotic cell death (Kanzler et al. 1996). In
nodular lymphocyte-predominant HL (NLPHL), the neoplas-
tic tumour cells are the lymphocyte-predominant (LP) cells.
Whereas LP cells still strongly express CD20 as a marker,
which is predominantly expressed by human B cells, HRS
cells in cHL have mainly lost the expression patterns of
physiological B cells and preferentially express the tumour
necrosis factor (TNF) receptor family marker CD30
(Schwering et al. 2003; Steimle-Grauer et al. 2003; Swerdlow
et al. 2008; Küppers et al. 2011).
HRS cells attract numerous cells into or in the lymphatic
tissue, resulting in an inflammatory microenvironment that
probably promotes their survival. An aberrant immune re-
sponse in the vicinity of HRS cells seems to maintain an
immunosuppressive environment (Chetaille et al. 2009), e.g.,
by the attraction of anergic T cells that suppress a cytotoxic
anti-tumour response (Küppers 2009). Since HRS cells, in the
overwhelming majority of cases, are neoplastic B cells, the
cytokines that are produced by these T cells might even assist
HRS cell growth and survival. Further exploration of cyto-
kines and growth factors involved in chemoattraction, prolif-
eration, differentiation, organ composition and sustainment
and in pro- and anti-inflammatory regulation is therefore
needed to improve our understanding not only of the com-
plexity of HL pathogenesis but also of the general mecha-
nisms of tumour escape.
Insulin-like growth factor I (IGF-I) is a pleiotropic growth
factor involved in the regulation of proliferation, differentia-
tion, protection against apoptosis and cell survival. IGF-I is
produced not only in the liver with growth hormone (GH) as a
major stimulus for its synthesis and release (termed the endo-
crine route) but also in extrahepatic sites where it is thought to
exert autocrine and paracrine effects via the IGF-I receptor
(IGF-1R), a tetrameric tyrosine receptor kinase that is under
investigation for cancer therapy (e.g., Okusaka et al. 2014;
Gao et al. 2014). Previous work in cHL has revealed a role for
tyrosine receptor kinases as potential therapeutic targets
(Renné et al. 2005) and additional receptor-ligand interactions
are being investigated in HL, such as the cannabinoid receptor
(Benz et al. 2013).
A role for both IGF-I and its receptor in tumour prolifera-
tion and metastasis has been under debate for decades (Pollak
2009; Gallagher and LeRoith 2011; Clayton et al. 2011;
Dijogue et al. 2013). For instance, a predisposing effect of
GH overproduction in acromegaly for B cell diseases has been
suggested in the light of a clinical case of thyroid cancer and
follow-up non-HL attributed to elevated IGF-I levels
(Taslipinar et al. 2009). Moreover, IGF-I has been proposed
to regulate pro-B cell differentiation during which
haematopoetic precursor cells (pro-B cells) initiate the rear-
rangement of Ig heavy chains, express μ-heavy chain protein
and subsequently rearrange and express Ig light chain prod-
ucts before they exit the bone marrow as immunocompetent B
lymphocytes (Landreth et al. 1992). This rearrangement of Ig
genes coincides with the initial expression of B220 in mice, an
event that correlates with commitment to the B cell lineage.
IGF-I protects human lymphocytes against apoptosis (Avila-
Gomez et al. 2009) indicating the potential role of IGF-I in the
transition of apoptosis-evading B lymphocytes to HL cells.
Most recently, IGF-I has been shown to specifically stimulate
tumour cell growth in Hodgkin cell lines via the IGF-1R
in vitro but HL patients expressing IGF-1R on cHL tumour
cells demonstrate a better clinical outcome which supports a
role of the IGF-I system in HL; however, the data are still
contradictory (Liang et al. 2014). IGF-I has not as yet been
localised within HL tissue. Nevertheless, knowledge of the
presence of the ligand, be it within the tumour cells or within
the microenvironment, might help to unravel the potential
autocrine/paracrine role of the local IGF-I/IGF-1R axis for
the pathogenesis of HL.
Thus, in the present study, we define the cellular sites of
IGF-I in HL histopathological samples by double-
immunofluorescence for IGF-I and the established markers
(CD20, CD30) regularly expressed by the respective tumour
cells. Furthermore, using specific markers (CD3, CD15,
CD20, CD68), we identify IGF-I in specific cells of the
microenvironment in cHL. Additionally, we confirm the
presence of the IGF-1R in cHL cells as recently described




This study was approved by the official authorities of the
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(ISBER). The tissue bank sample contains 34 cHL samples
(13 mixed cellularity, 21 nodular sclerosis). Four additional
samples (1 mixed cellularity type cHL, 3 NLPHL) from
anonymised archival histopathological material were provided
by the Institute of Pathology, Hegau-Bodensee Clinic, Singen.
The diagnosis followed the criteria of the current WHO lym-
phoma classification (Swerdlow et al. 2008). For 34 patients,
clinical data (gender, age at diagnosis) were known (21 male,
13 female patients between 13 and 83 years, average 42 years).
No clinical data were available from 4 patients.
Tissue preparation
Lymph nodes were formalin-fixed and embedded into
Paraplast. A tissue microarray (TMA) was constructed by
taking duplicate cores of 650 μm from each biopsy (n=34)
as described previously (Butsch et al. 2011; Soldini et al.
2013) and cut at a thickness of 2.5 μm. In addition, one mixed
cellularity type cHL and three NLPHL cases were conven-
tionally cut on a microtome (Mettler Toledo, Germany) at a
thickness of 5 μm; consecutive sections were mounted on
Super Frost Plus slides (Menzel-Gläser, Germany) and dried
overnight at 42 °C. Both tissue preparations were subjected to
further morphological analysis after being dewaxed in Xylol
and rehydration in a descending series of ethanol (100, 96, 80,
70 %, all reagents obtained from Fluka, Switzerland). The
quality of the sampled area and the presence of neoplastic
follicles were ascertained by haematoxylin and eosin (HE)
staining.
Double-immunofluorescence
Double-immunofluorescence for IGF-I with CD markers
was performed as previously established for human lymph
nodes (Oberlin et al. 2009) with the modification that for
cHL CD30, for NLPHL CD20, and for granulocytes
CD15 (all DAKO Cytomation, Glostrup, Denmark) were
additionally applied. In brief, for demasking of the anti-
gens, sections were treated with antigen-retrieval solution
according to the recommendations of the manufacturer
(DAKO); they were then blocked with 2 % bovine serum
albumin in phosphate-buffered saline (pH 7.4) and incu-
bated overnight at 4 °C with rabbit IGF-I antiserum
(Oberlin et al. 2009) followed by visualisation with fluo-
rescein isothiocyanate (FITC)-coupled goat anti-rabbit
IgG (Bioscience Products, Emmenbrücke, Switzerland).
Subsequently, antibodies against CD3 (Abcam, UK),
CD15, CD20, CD30 and CD68 (all from DAKO) were
applied overnight at 4 °C and visualised with Texas-red-
conjugated goat anti-mouse IgGs (Bioscience and
Amersham, Little Chalfont, UK). IGF-1R was detected
by double-immunofluorescence with chicken anti-human
IGF-1R antiserum followed by visualisation with FITC-
coupled goat anti-chicken IgG (both Abcam, UK). Subse-
quently, the antibody against CD30 was applied overnight
at 4 °C and visualised with Texas-red-conjugated goat
anti-mouse IgG. Specificity of the antisera was tested by
omitting the primary antisera as a negative control and by
using sections of human breast cancer, intestine and
lymph node and rat pancreas as positive controls as
previously described (Eppler et al. 2002; Jevdjovic
et al. 2004, 2005; Oberlin et al. 2009; Link et al.
2013) and an embryonic tumour known to contain
CD30-immunoreactive cells.
Immunohistochemistry
Additionally, immunohistochemistry was applied by using
rabbit anti-human IGF-1R antibody (Ventana, Tucson, Ariz.,
USA). One HLTMA section (3.0 μm) was transferred to one
glass slide followed by immunohistochemical analysis on an
instrument according to Ventana automat protocols. Each
TMA slide was pretreated with CC1 buffer (Ventana) for
64 min followed by incubation for 24 min and subsequently
detection with an ultraView Universal DAB kit (Ventana).
Imaging
Conventional light and fluorescence images were
photographed with a Zeiss Axioscope by using Axiovision
software 3.1. (Zeiss, Zürich, Switzerland). TMA slides were
scanned by using a NanoZoomer (Hamamatsu, Hamamatsu
City, Japan).
Results
Immunoreactivity for IGF-I and for IGF-1R was examined in
cHL and NLPHL cells of various types (Figs. 1, 2, 3, 4, 5, 6
and 7).
IGF-I immunoreactivity in cHL cells of mixed cellularity type
IGF-I immunoreactivity was detected regularly in HRS
cells of cHL of mixed cellularity in all cases investigated
by double-immunofluorescence for IGF-I and CD30
(Fig. 1). Additionally, IGF-I immunoreactivity was de-
tected in endothelial cells of high endothelial venules and
numerous other cells of the microenvironment surround-
ing the tumour (Figs. 4 and 5). In particular, neutrophils
within the tumour microenvironment were identified by
their immunoreactivity for CD15 and were shown to
contain IGF-I immunoreactive material, as did tumour
cells of cHL, which are also known to express CD15
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with variable intensity (Fig. 4). Furthermore, macro-
phages within the tumour microenvironment identified
by their immunoreactivity for CD68 contained IGF-I
immunoreactive material (Fig. 5), whereas CD20+ B
(Fig. 7) and CD3+ T lymphocytes (data not shown) were
not found to contain IGF-I immunoreactive material.
Fig. 1 Insulin-like growth factor
I (IGF-I) in classical Hodgkin’s
lymphoma (cHL) cells of mixed
cellularity type. a Haematoxylin
and eosin (HE) staining (arrows
Hodgkin and Reed-Sternberg










immunoreactive for CD30 (c, d).
d Overlay of b, c (arrows CD30+
IGF-I-immunoreactive HRS cells,
asterisks cells immunoreactive for
IGF-I exclusively, V IGF-I-
immunoreactive endothelium of
high endothelial venules). Bar
50 μm
Fig. 2 IGF-I in cHL cells of
nodular sclerosis type. a HE stain









negative cells within the tumour
microenvironment (asterisks). d
Overlay of b, c (arrows CD30+
IGF-I-immunoreactive HRS cells,
asterisks IGF-I-immunoreactive
but CD30-negative cells of the
tumour microenvironment). Bar
50 μm
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IGF-I immunoreactivity in cHL cells of nodular sclerosis type
IGF-I immunoreactivity was detected regularly in HRS cells
of nodular sclerosis cHL in all cases investigated by double-
immunofluorescence for IGF-I and CD30 (Fig. 2). As in cHL
of mixed cellularity type (Figs. 1, 4 and 5), numerous other
cell types of the tumour microenvironment expressed IGF-I
immunoreactivity.
IGF-I immunoreactivity in LP cells of NLPHL
IGF-I immunoreactivity was detected in LP cells of NLPHL
cases investigated by double-immunofluorescence for IGF-I
and CD20 (Fig. 3). Furthermore, numerous CD20-negative
cells of the tumour microenvironment expressed IGF-I immu-
noreactivity. Expectedly, numerous B cells in the microenvi-
ronment were immunoreactive for CD20 in addition to the LP
cells. Among these, cells without immunoreactivity for CD20
could be observed around the LP cells; the former are most
probably rosette-forming T cells (Fig. 3).
IGF-1R immunoreactivity in cHL
IGF-1R immunoreactivity was detected with variable intensi-
ty of expression in HRS cells of cHL identified by immuno-
histochemistry (Fig. 6a) and by double-immunofluorescence
with CD30. In particular, high IGF-1R expression was ob-
served in the mononuclear Hodgkin cells, whereas the
inspected RS cells revealed lower IGF-1R density (Fig. 6a,
b, d). Additionally, IGF-1R immunoreactivity was detected in
the microenvironment, particularly in the high endothelial
venules (Fig. 6c, d).
Discussion
Here, for the first time, we located IGF-I immunoreactive
material intracellularly in HRS cells of mixed cellularity and
the nodular sclerosis type of cHL in histopathological tissue,
in LP cells of NLPHL and in distinct cells of the tumour
microenvironment in general. IGF-I has been under debate
as a factor involved in tumor pathogenesis for decades, with
elevated circulating IGF-I levels being an increased risk factor
for the development of certain cancers such as those of the
colon, breast and prostate. Conversely, individuals with GH
receptor deficiency exhibiting the so-called Laron syndrome
of GH insensitivity and IGF-I defiency appear to be protected
against cancer development (Gallagher and LeRoith 2011;
Clayton et al. 2011; Dijogue et al. 2013).
IGF-I immunoreactivity has been previously observed in
stroma cells and higher differentiated breast cancer cells
(Eppler et al. 2002), whereas decreased IGF-I immunoreac-
tivity has been detected in human primary liver cancer as
compared with normal liver (Ikeda et al. 2013). Moreover,
IGF-I mRNA and (to a lesser extent) IGF-I peptide have been
Fig. 3 IGF-I in lymphocyte-
predominant (LP) cells of the
nodular lymphocyte-predominant
type (NLPHL). a HE stain




(arrows). Numerous B cells (B) in
addition to the tumour LP cells
are immunoreactive for CD20.
Note also the reduced amount of
CD20-immunoreactive cells
around the LP cells; the former
cells are most probably T cells (T)
that are sometimes arranged in a
rosette-like structure. c IGF-I
immunoreactivity (green). Note
IGF-I-immunoreactive LP cells
(arrows). d Overlay of b, c
(arrows CD20+ IGF-I-
immunoreactive LP cells). Bar
50 μm
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found in stroma and tumour cells of a lymph node metastasis
of an IGF-I-producing tumour (Nauck et al. 2007); this
supports the assumption that local autocrine/paracrine IGF-I
is generally involved in the proliferation and differentiation of
846 Cell Tissue Res (2015) 359:841–851
tumour cells and in the establishment of a tumour-sustaining
microenvironment.
IGF-I has been proposed generally to stimulate immune
organs and cells and, in particular, B cell development and
differentiation and B cell leukemia cell lines (Landreth et al.
1992; Taguchi et al. 2006); for example, it potentiated the
expansion of interleukin-7 (IL-7)-dependent pro-B cells in
one study (Gibson et al. 1993), whereas in another study, it
failed to induce a proliferative response in childhood acute
lymphoblastic leukemia-derived pre-B cell lines in combina-
tion with IL-7 (Consolini et al. 1997). Although IGF-I stimu-
lates DNA synthesis in a Burkitt-type ALL-cell line, in an
ANLL-cell line and in a Hodgkin’s disease cell line (Vetter
et al. 1986; Shimon and Shpilberg 1995), the antibody
blocking of IGF-I or the IGF-1R reduced proliferation of
human acute lymphoblastic leukemia cell lines (Baier et al.
Fig. 4 IGF-I in CD15+ granulocytes within a tumour microenvironment
of mixed cellularity cHL. a HE stain (arrows HRS cells). Note
neutrophils (N) within the blood vessel and histiocytes (h) designated
with asterisks within the microenvironment. Bar 80 μm. b-d
Immunofluorescence. b CD15 immunoreactivity (red). Note the
numerous CD15-immunoreactive neutrophils (N) within the tumour
microenvironment. c IGF-I immunoreactivity in cells also
immunoreactive for CD15 designated as neutrophils (N). Note cells
immunoreactive for IGF-I (asterisks) but not immunoreactive for CD15
(c, d). dOverlay of b, c. Bar 50 μm. eHE stain (arrowsHRS cells). Note
neutrophil (N) within the blood vessel . Bar 80 μm. f–h
Immunofluorescence. f CD15 immunoreactivity (red). Note CD15-
immunoreactive neutrophil (N) within the tumour microenvironment
and HRS cell expressing CD15 (arrow). g IGF-I immunoreactivity in
cells immunoreactive for CD15 and also in a cell designated as a
neutrophil (N). Note cells immunoreactive for IGF-I (asterisks) but not
immunoreactive for CD15 (g, h). h Overlay of f, g. Bar 50 μm
Fig. 5 IGF-I in CD68+
macrophages within the tumour
microenvironment of mixed
cellularity cHL and non-tumoral
human lymph node. a HE stain of
mixed cellularity cHL (arrow
HRS cell). Note histiocytes (h)
designated with asterisks within
the microenvironment. Bar
80 μm. b-d Immunofluorescence
of a tumour microenvironment of
mixed cellularity cHL. b CD68
immunoreactivity (red). Note
CD68-immunoreactive




immunoreactive for CD68 in b). d
Overlay of b, c. Bar 50 μm. e, f
Immunofluorescence of non-
tumoral human lymph node. e
IGF-I immunoreactivity in cells
immunoreactive for CD68 (f) are
designated with arrows. Note
cells immunoreactive for IGF-I
(asterisks) but not
immunoreactive for CD68. Bar
50 μm
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1992). The neutralisation of IGF-I function in vitro results in a
significant reduction in pro-B cell development from CD34+
cells in mice (Taguchi et al. 2006). So far, IGF-I mRNA and
peptide have been found to be produced by human peripheral
lymphocytes only in low amounts (Arkins et al. 1993; Kelley
and Arkins 1994) or after mitogen stimulation (Nyman and
Pekonen 1993). Nevertheless, most recently, IGF-I has been
shown to stimulate the in vitro tumour growth of Hodgkin cell
lines via the IGF-1R, which has been localised in cHL tumour
cells, whereas the ligand has been detected in the cell culture
supernatant (Liang et al. 2014) but remains to be localised.
Thus, in the present study, we aimed at localising the ligand
IGF-I in HRS cells of cHL, in the LP cells of NLPHL and in
the microenvironment, which, as described above, is essential
for the pathogenesis and maintenance of tumour cells and
which in HL only constitute a minority of the tumour mass
(Steidl et al. 2011).
In the present study, we detected IGF-I-immunoreactive
material in macrophages and high endothelial venules of HL
lesions, as previously described in non-tumoral lymph nodes
in which we proposed a role for IGF-I in the differentiation of
the special endothelium and attraction of lymphocytes and,
particularly, in the support of macrophages during immune
challenge (Oberlin et al. 2009). Thus, IGF-I might contribute
to the constitution and maintenance of the tumour microenvi-
ronment, in addition to its local presence in the tumour cells
themselves. The importance of local IGF-I in shaping the
microenvironment is supported by the additional localisation
of the IGF-1R in the endothelium of blood vessels, particu-
larly the high endothelial venules, within the tumour
microenvironment. With respect to the reported impor-
tance of the IGF-1R in endothelial function and repair
under various conditions (see Imrie et al. 2012), this
might be of special relevance for shaping and sustaining
the microenvironment.
So far, human and murine myeloid cells, particularly mac-
rophages, have been found to produce IGF-I, even in relative-
ly large amounts (Arkins et al. 1993; Kelley and Arkins 1994),
whereby cytokines such as TNF-α (Noble et al. 1993;
Fournier et al. 1995) and colony-stimulating factors (Arkins
et al. 1995a) have been proposed as stimulators and
interferon-γ as an inhibitor (Arkins et al. 1995b).
Fig. 6 IGF-I receptor (IGF-1R) in tumour cells and in the tumour
microenvironment of cHL. a, c Immunohistochemistry with anti-IGF-
1R antibody; nuclei are counterstained with haematoxylin. b, d Double-
immunofluorescence with anti-IGF-1R antibody (green) and CD30 (red).
a Note IGF-1R-immunoreactive HRS cells (arrows) and RS cell with
faint IGF-1R expression (arrowheads). Bar 60 μm. b Note IGF-1R-
immunoreactive HRS cells (arrows) visualised by CD30
immunoreactivity (asterisks designated cells in microenvironment
immunoreactive for IGF-1R exclusively). Bar 60 μm. c Note IGF-1R-
immunoreactive endothelium of high endothelial venules (V); other blood
vessels only rarely express IGF-1R. Bar 40 μm. d Note CD30-
immunoreactive HRS cells with faint IGF-1R expression (arrowheads)
and IGF-1R-immunoreactive endothelium of venule (V). Arrow points to
sheets of non-immunoreactive cells of the microenvironment. Bar 40 μm
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Interestingly, IGF-I has been reported to be “unexpectedly”
stimulated by IL-24, a mediator of apoptosis in human B cells
and activated B cells express the IGF-1R and undergo apo-
ptosis (Hadife et al. 2013); this could be of particular signif-
icance in light of the recent finding that patients expressing the
IGF-1R on cHL tumour cells demonstrate a better clinical
outcome (Liang et al. 2014). Nevertheless, in the same study,
IGF-I has been shown to stimulate tumour cell growth in vitro
(Liang et al. 2014), whereas IGF-I and its receptor are upreg-
ulated by B cells undergoing apoptosis (Hadife et al. 2013).
In the present study, although the CD20+ tumour LP cells
expressed IGF-I (Fig. 3), we did not detect IGF-I peptide
within CD20+ B cells of the tumour microenvironment
(Fig. 7a) or in CD3+ T lymphocytes (data not shown). The
absence of IGF-I in lymphocytes of the human lymph node is
similar to our previous findings in CD3+ T lymphocytes and
CD20+ B lymphocytes in the non-malignant lymph node
(Oberlin et al. 2009; present study). The absence of IGF-I in
non-reactive B cells in our study is also in accordance with
observations by other groups that freshly isolated B lympho-
cytes do not secrete IGF-I in vitro (Merrimee et al. 1989).
Interestingly, B lymphocytes transformed by Epstein-Barr
virus secrete IGF-I in vitro (Merrimee et al. 1989) and human
B cell line IM-9 lymphocytes express IGF-I mRNA (Clayton
et al. 1994). These observations lead to the assumption of a
specific role for IGF-I in transformed B cells, which constitute
the basis for HL pathogenesis as outlined above. This role is
now strongly supported by our present detection of the fre-
quent IGF-I presence in tumour cells of cHL and NLPHL,
whereas some cells showing the morphology of activated
CD20+ B lymphocytes (Fig. 7b) contain IGF-I-
immunoreactive material, thus exhibiting a transition form.
Hence, we propose a role of IGF-I, after the activation of B
cells, in the prevention of apoptosis following the crippled
mutation and thus a role in the transition from transformed B
cells to HL tumour cells (Fig. 7c).
Despite the small number of tumour cells in the TMA
investigated, the differential degree in the expression of IGF-
Fig. 7 IGF-I in B cells within the
tumour tissue of mixed cellularity
cHL and non-tumoral human
lymph node. a, b Double-
immunofluorescence for CD20
(red) and IGF-I (green) in (a)
tumour microenvironment of
mixed cellularity cHL and (b)
non-tumoral human lymph node.
Asterisks designated cells
immunoreactive for IGF-I
exclusively, but not for CD20.
Bar 30 μm. c Representation of
the potential protection of
transformed B cells from
apoptosis by means of
intracellular IGF-I. Whereas IGF-
I as reported in the literature has
not been found in naive and non-
reactive B cells, it has been
detected after various stimuli such
as Epstein-Barr virus (EBV)
infection and mitogenic
stimulation and is involved in B
cell differentiation, expansion and
survival. Note the observed
higher density of the IGF-1R in
the present study in the
mononuclear Hodgkin cells as
compared with the multinuclear
RS cells
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I and the IGF-1R, with stronger expression of the IGF-1R in
the mononuclear Hodgkin than in the RS cells, should foster
future studies. This is particularly pertinent because the enig-
matic origin of the multinuclear RS cells has recently been
illuminated by the findings that they arise by the re-fusion of
daughter cells from small mononuclear Hodgkin cells that
have undergone mitosis and constitute the proliferative com-
partment of the cHL tumour clone (Rengstl et al. 2013).
Acknowledgments We gratefully acknowledge the helpful support of
Martina Storz (Tissue Biobank) and André Fitsche (In situ Laboratory,
Institute of Surgical Pathology, Zurich University Hospital). We further
thank Charlotte Burger and Heinz Sonderegger (Institute of Anatomy,
University of Zurich) and Regine Göhrt (Institute of Pathology, Hegau-
Bodensee Clinic Singen) for skilful technical assistance.
References
Arkins S, Rebeiz N, Biragyn A, Reese DL, Kelley KW (1993) Murine
macrophages express abundant insulin-like growth factor-I class I
Ea and Eb transcripts. Endocrinology 133:2334–2343
Arkins S, Rebeiz N, Brunke-Reese DL, Minshall C, Kelley KW (1995a)
The colony-stimulating factors induce expression of insulin-like
growth factor-I messenger ribonucleic acid during hematopoesis.
Endocrinology 136:1153–1160
Arkins S, Rebeiz N, Brunke-Reese DL, Minshall C, Biragyn A, Kelley
KW (1995b) Interferon-gamma inhibits macrophage insulin-like
growth factor-I synthesis at the transcriptional level. Mol
Endocrinol 9:350–360
Avila-Gomez IC, Velez-Pardo C, Jimenez-Del-Rio M (2009) Effects of
insulin-like growth factor-I on rotenone-induced apoptosis in human
lymphocyte cells. Basic Clin Pharmacol Toxicol 106:53–61
Baier TG, Jenne EW, Blum W, Schönberg D, Hartmann KK (1992)
Influence of antibodies against IGF-I, insulin or their receptors on
proliferation of human acute lymphoblastic leukemia cell lines.
Leuk Res 16:807–814
Benz AH, Renné C, Maronde E, Koch M, Grabiec U, Kallendrusch S,
Rengstl B, Newrzela S, Hartmann S, Hansmann ML, Dehghani F
(2013) Expression and functional relevance of cannabinoid receptor
1 in Hodgkin lymphoma. PLoS One 8:e81675
Butsch R, Waelti SL, Schaerer S, Braun J, Korol D, Probst-Hensch N,
Moch H, Kurrer M (2011) Intratumoral plasmacytoid dendritic cells
associate with increased survival in patients with follicular lympho-
ma. Leuk Lymphoma 52:1230–1238
Chetaille B, Bertucci F, Finetti P, Esterni B, Stamatoullas A, Piquenot JM,
Copin MC, Morschhauser F, Casanovas O, Petrella T, Molina T,
Vekhoff A, Feugier P, Bouabdallah R, Birnbaum D, Olive D, Xerr L
(2009) Molecular profiling of classical Hodgkin lymphoma tissues
uncovers variations in the tumor microenvironment and correlations
with EBV infection and outcome. Blood 113:2765–3775
Clayton PE, Day RN, Silva CM, Hellmann P, Day KH, Thorner MO
(1994) Growth hormone induces tyrosine phosphorylation but does
not alter insulin-like growth factor-I gene expression in human IM9
lymphocytes. J Mol Endocrinol 13:127–136
Clayton PE, Banerjee I, Murray PG, Renehan AG (2011) Growth hor-
mone, the insulin-like growth factor axis, insulin and cancer risk.
Nat Rev Endocrinol 7:11–24
Consolini R, Legitimo A, Cattani M, Simi P, Mattii L, Petrini M, Putti C,
Basso G (1997) The effect of cytokines, including IL4, IL7, stem
cell factor, insulin-like growth factor on childhood acute lympho-
blastic leukaemia. Leuk Res 21:753–761
Dijogue S, Kamdje AHN, Vecchio L, Kipanyula MJ, Farahna M,
Aldebasi Y, Etet PFS (2013) Insulin resistance and cancer: the role
of insulin and IGFs. Endocr Relat Cancer 20:R1–R17
Eppler E, Zapf J, Bailer N, Falkmer UG, Falkmer S, Reinecke M (2002)
IGF-I in human breast cancer: low differentiation stage is associated
with decreased IGF-I content. Eur J Endocrinol 146:813–821
Farrell K, Jarrett RF (2011) The molecular pathogenesis of Hodgkin
lymphoma. Histopathology 58:15–25
Fournier T, Riches DW, Winston BW, Rose DM, Young SK, Noble PW,
Lake FR, Henson PM (1995) Divergence in macrophage insulin-
like growth factor-I (IGF-I) synthesis induced by TNF-alpha and
prostaglandin E2. J Immunol 155:2123–2133
Gallagher EJ, LeRoith D (2011) Minireview: IGF, insulin, and cancer.
Endocrinology 152:1–6
Gao L,WangX,WangX, Zhang L, QiangC, Chang S, RenW, Li S, Yang
Y, Tong D, Chen C, Li Z, Song T, Zhi K, Huang C (2014) IGF-1R, a
target of let-7b, mediates crosstalk between IRS-2/Akt and MAPK
pathways to promote proliferation of oral squamous cell carcinoma.
Oncotarget 5:2562–2574
Gibson LF, Piktel D, Landreth KS (1993) Insulin-like growth factor-1
potentiates expansion of interleukin-7-dependent pro-B cells. Blood
82:3006–3011
Hadife N, Nemos C, Frippiat JP, Hamadé T, Perrot A, Dalloul A (2013)
Interleukin-24 mediates apoptosis in human B-cells through early
activation of cell cycle arrest followed by late induction of the
mitochondrial apoptosis pathway. Leuk Lymphoma 54:587–597
Ikeda Y, Kajiyama K, Yamashita Y, Ikegami T, Uchiyama H, Soejima Y,
KawanakaH, Ikeda T,MoritaM, Oki E, Saeki H, Suehiro T,Mimori
K, Sugimachi K, Shirabe K, Maehara Y (2013) Differential expres-
sion of insulin-like growth factor 1 in human primary liver cancer.
Fukuoka Soc Zasshi 104:334–338
Imrie H, Viswambharan H, Sukumar P, Abbas A, Cubbon RM,
Yuldasheva N, Gage M, Smith J, Galloway S, Skromna A, Rashid
ST, Futers TS, Xuan S, GatenbyVK, Grant PJ, ChannonKM, Beech
DJ, Wheatcroft SB, Kearney MT (2012) Novel role of the IGF-1
receptor in endothelial function and repair: studies in endothelium-
targeted IGF-1 receptor transgenic mice. Diabetes 61:2359–2368
Jevdjovic T, Maake C, Eppler E, Zoidis E, Reinecke M, Zapf J (2004)
Effects of insulin-like growth factor-I treatment on the endocrine
pancreas of hypophysectomized rats: comparison with growth hor-
mone replacement. Eur J Endocrinol 151:223–231
Jevdjovic T, Maake C, Zwimpfer C, Krey G, Eppler E, Zapf J, Reinecke
M (2005) The effect of hypophysectomy on pancreatic islet hor-
mone and insulin-like growth factor I content andmRNA expression
in rat. Histochem Cell Biol 123:179–188
Kanzler H, Küppers R, Hansmann ML, Rajewski K (1996) Hodgkin and
Reed-Sternberg cells in Hodgkin’s disease represent the outgrowth
of a dominant tumor clone derived from (crippled) germinal center
B cells. J Exp Med 184:1495–1505
Kelley KW, Arkins S (1994) A role for IGF-1 during myeloid cell growth
and differentiation. In: Baxter RC, Gluckman PD, Psenfeld RG (eds)
The role for insulin-like growth factors and regulatory proteins.
Elsevier, Amsterdam, pp 315–327
Küppers R (2009) The biology of Hodgkin’s lymphoma. Nat Rev Cancer
9:15–27
Küppers R, Engert A, Hansmann ML (2011) Hodgkin lymphoma. J Clin
Invest 122:3439–3447
Landreth KS, Narayanan R, Dorshkind K (1992) Insulin-like growth
factor-I regulates pro-B-cell differentiation. Blood 80:1207–
1212
Liang Z, Diepstra A, Xu C, Imhoff G van, Plattel W, Van den Berg A,
Visser L (2014) Insulin-like growth factor 1 receptor is a prognostic
factor in classical Hodgkin lymphoma. PLoS One 9:e87474
Link KR, Allio I, Rand JS, Eppler E (2013)The effect of experi-
mentally induced chronic hyperglycaemia on serum and pan-
creatic insulin, pancreatic islet IGF-I and plasma and urinary
850 Cell Tissue Res (2015) 359:841–851
ketones in the domestic cat (Felis felis). Gen Comp Endocrinol
188:269–281
Merrimee TJ, Grant MB, Broder CM, Cavalli-Sforza LL (1989) Insulin-
like growth factor secretion by human B-lymphocytes: a comparison
of cells from normal and pygmy subjects. Clin Endocrinol Metab
69:978–984
Nauck MA, Reinecke M, Perren A, Frystyk J, Berishvili G, Zwimpfer C,
Figge AM, Flyvberg A, Lankisch PG, Blum WF, Klöppel G,
Schmiegel W, Zapf J (2007) Hypoglycemia due to paraneoplastic
secretion of insulin-like growth factor-I in a patient with metastasiz-
ing large-cell carcinoma of the lung. J Clin Endocrinol Metab 92:
1600–1605
Noble PW, Lake FR, Henson PM, Riches DWH (1993) Hyaluronate
activation of CD44 induces insulin-like gowth factor-1 expression
by a tumor necrosis factor-alpha dependent mechanism in murine
macrophages. J Clin Invest 91:2368–2377
Nyman T, Pekonen F (1993) The expression of insulin-like growth
factors and their binding proteins in normal human lymphocytes.
Acta Endocrinol (Copenh) 128:168–172
Oberlin D, Fellbaum C, Eppler E (2009) Insulin-like growth factor I
messenger RNA and protein are expressed in the human lymph
node and distinctly confined to subtypes of macrophages, antigen-
presenting cells, lymphocytes and endothelial cells. Immunology
128:342–350
Okusaka T, IkedaM, Fukutomi A, Kobayashi Y, ShibayamaK, Takubo T,
Gansert J (2014) Safety, tolerability, pharmacokinetics and antitu-
mor activity of ganitumab, an investigational fully human monoclo-
nal antibody to insulin-like growth factor type 1 receptor, combined
with gemcitabine as first-line therapy in patients with metastatic
pancreatic cancer: a phase 1b study. Jpn J Clin Oncol 44:442–447
Pollak M (2009) Insulin and insulin-like growth factor signaling in
neoplasia. Nat Rev Cancer 8:915–928
Rengstl B, Newrzela S, Heinrich T, Weiser C, Thalheimer FB, Schmid F,
Warner K, Hartmann S, Schroeder T, Küppers R, Rieger MA,
Hansmann ML (2013) Incomplete cytokinesis and re-fusion of
small mononucleated Hodgkin cells lead to giant multinucleated
Reed-Sternberg cells. Proc Natl Acad Sci U S A 110:20729–20734
Renné C, Willenbrock K, Küppers R, Hansmann ML, Bräuninger A
(2005) Autocrine- and paracrine-activated receptor tyrosine kinases
in classic Hodgkin lymphoma. Blood 105:4051–4059
Renné C, Hansmann ML, Bräuninger A (2009) Receptor-tyrosinkinases
in Hodgkin-lymphomas. Pathologe 30:393–400
Roman E, Smith AG (2011) Epidemiology of lymphomas.
Histopathology 58:4–14
Schmitz R, Stanelle J, HansmannML, Küppers R (2009) Pathogenesis of
classical and lymphocyte-predominant Hodgkin lymphoma. Annu
Rev Pathol Mech Dis 4:151–174
Schwering I, Bräuninger A, Klein U, Jungnickel B, Tinguely M, Diehl V,
Hansmann ML, Dalla-Favera R, Rajewski K, Küppers R (2003) Loss
of the B-lineage-specific gene expression program in Hodgkin and
Reed-Sternberg cells of Hodgkin lymphoma. Blood 101:1505–1512
Shimon I, Shpilberg O (1995) The insulin-like growth factor system in
regulation of normal andmalignant hematopiesis. Leuk Res 19:233–
240
Soldini D, Montagna C, Schüffler P, Martin V, Georgis A, Thiesler T,
Curioni-Fontecedro A, Went P, Bosshard G, Dehler S, Mazzachelli
L, Tinguely M (2013) A new diagnostic algorithm for Burkitt and
diffuse large B-cell lymphomas based on the expression of CSE1L
and STAT3 and on MYC rearrangement predicts outcome. Ann
Oncol 24:193–201
Steidl C, Connors JM, Gascoyne RD (2011) Molecular pathogenesis of
Hodgkin’s lymphoma: increasing evidence of the importance of the
microenvironment. J Clin Oncol 29:1812–1826
Steimle-Grauer SA, Tinguely M, Seada L, Fellbaum C, Hansmann ML
(2003) Expression patterns of transcription factors in progressively
transformed germinal centers and Hodgkin lymphoma. Virchows
Arch 442:284–293
Steu S, Baucamp M, Dach G von, Bawohl M, Dettwiler S, Storz M,
Moch H, Schraml P (2008) A procedure for tissue freezing and
processing applicable to both intra-operative frozwn section diag-
nosis and tissue banking in surgical pathology. Virchows Arch 452:
305–312
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele
J, Vardiman JW (2008) WHO classification of tumours of
haematopoietic and lymphoid tissues, 4th edn. WHO classification
of tumours, vol 2. International Agency for Research on Cancer
(IARC), Lyon
Taguchi T, Takenouchi H, Matsui J, Tang WR, Itagaki M, Shiozawa Y,
Suzuki K, Sakaguchi S, Ktagiri YU, Takahashi T, Okita H, Fujimoto
J, Kiyokawa N (2006) Involvement of insulin-like growth factor-I
and insulin-like growth factor binding proteins in pro-B-cell devel-
opment. Exp Hematol 34:508–518
Taslipinar A, Bolu E, Kebapcilar L, Sahin M, Uckaya G, Kutlu M (2009)
Insulin-like growth factor-1 is essential to the increased mortality
caused by excess growth hormone: a case of thyroid cancer and non-
Hodgkin’s lymphoma in a patient with pituitary acromegaly. Med
Oncol 26:62–66
Vetter U, Schlickenrieder JHM, Zapf J, Hartmann W, Heit W, Hitzler H,
Byrne P, Gaedicke G, Heinze E, TellerWM (1986) Human leukemic
cells: receptor binding and biological effects of insulin and insulin-
like growth factors. Leuk Res 19:1201–1207
Von Teichman A, Storz M, Dettwiler S, Moch H, Schraml P (2012)
Whole genome and transcriptome amplification: practicable tools
for sustainable tissue biobanking? Virchows Arch 461:571–580
Cell Tissue Res (2015) 359:841–851 851
